Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Ginkgo Bioworks has expanded its partnership with Google Cloud to introduce two AI tools aimed at accelerating drug development. These tools, a protein large language model and a model API, leverage AI and proprietary data to enhance therapeutic discovery. The collaboration with Google Cloud and the development of AlphaFold 3 by Google DeepMind are key components of this initiative.

Portfolio Pulse from Vandana Singh

September 17, 2024 | 5:48 pm

Ginkgo Bioworks shares rose following the launch of a protein LLM and model API on Google Cloud, aimed at speeding up drug development.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 4:19 pm

Ginkgo Bioworks shares surged after announcing a new protein large language model built on Google Cloud, aimed at aiding pharmaceutical and biotech companies in drug development. The model and API are now publicly available, with plans for further expansion.

Portfolio Pulse from Adam Eckert

September 17, 2024 | 3:17 pm

Several US-listed stocks saw significant gains on Tuesday. Compass Minerals rose 24.5% after announcing better-than-expected preliminary Q3 revenue. Talkspace gained 20.9% following a partnership with Amazon Health Services. Gannett rose 14.5% after a Citigroup upgrade. Gevo surged 14% after securing a US patent. Other notable gainers include Ginkgo Bioworks, Designer Brands, and Hewlett Packard Enterprise.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 2:22 pm

Ginkgo Bioworks has launched a new protein language model and API, built on Google Cloud, to accelerate drug development. This tool will be available to scientists and researchers via API and soon on Google Cloud's Vertex AI Model Garden.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 12:03 pm

Ginkgo Bioworks has been awarded a $118 million contract by the U.S. Department of Health and Human Services (HHS). This contract is likely to enhance Ginkgo's financial position and market presence.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:32 pm

Ginkgo Bioworks has regained compliance with the New York Stock Exchange's listing standards, which is a positive development for the company.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 8:33 pm

Ginkgo Bioworks faced a significant downfall after a report by Scorpion Capital accused it of being overpriced and engaging in misleading business practices. The company's stock plummeted, and it faced legal challenges, including a DOJ investigation and a shareholder lawsuit. Ginkgo has agreed to a $17.75 million settlement to resolve the lawsuit. Despite these challenges, the company remains focused on synthetic biology and aims for future growth.

Portfolio Pulse from Stan Vick

August 26, 2024 | 3:51 pm

BTIG analyst Mark Massaro maintains a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and adjusts the price target to $7 following a 1-40 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 5:17 pm

Ginkgo Bioworks shares are trading higher after the company reported better-than-expected Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 12:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.